Trillium Asset Management LLC cut its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 14.1% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 199,435 shares of the company's stock after selling 32,731 shares during the quarter. Trillium Asset Management LLC's holdings in Novo Nordisk A/S were worth $13,849,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Strategic Investment Solutions Inc. IL grew its position in shares of Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after acquiring an additional 300 shares in the last quarter. Copeland Capital Management LLC boosted its position in Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after acquiring an additional 255 shares during the period. North Capital Inc. acquired a new position in Novo Nordisk A/S during the 1st quarter worth $27,000. Park Square Financial Group LLC bought a new stake in shares of Novo Nordisk A/S in the 4th quarter worth $29,000. Finally, Transce3nd LLC bought a new stake in shares of Novo Nordisk A/S in the 4th quarter worth $33,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several research analysts recently weighed in on the company. HSBC lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price target on the stock. in a research report on Thursday, July 31st. Guggenheim downgraded Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. BMO Capital Markets reissued a "market perform" rating and set a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Barclays reissued an "equal weight" rating on shares of Novo Nordisk A/S in a research report on Wednesday, July 30th. Finally, UBS Group cut Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 5th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $83.75.
Check Out Our Latest Stock Analysis on NVO
Novo Nordisk A/S Price Performance
Shares of NVO traded up $1.12 during mid-day trading on Wednesday, reaching $50.90. The company had a trading volume of 19,399,726 shares, compared to its average volume of 25,473,044. Novo Nordisk A/S has a twelve month low of $45.05 and a twelve month high of $139.74. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The company's 50-day moving average is $66.26 and its 200-day moving average is $71.05. The company has a market capitalization of $227.27 billion, a P/E ratio of 13.98, a P/E/G ratio of 1.71 and a beta of 0.63.
Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. The business had revenue of $11.69 billion during the quarter, compared to analysts' expectations of $77.51 billion. On average, equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.
Novo Nordisk A/S Cuts Dividend
The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, August 26th. Investors of record on Monday, August 18th will be given a dividend of $0.4119 per share. The ex-dividend date is Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S's dividend payout ratio is 45.05%.
About Novo Nordisk A/S
(
Free Report)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
See Also

Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.